FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310081041> ?p ?o ?g. }

• W4310081041 endingPage "36" @default.
• W4310081041 startingPage "26" @default.
• W4310081041 abstract "Optimal target blood pressure to reduce adverse cardiac remodelling in children with chronic kidney disease is uncertain. We hypothesised that lower blood pressure would reduce adverse cardiac remodelling.HOT-KID, a parallel-group, open-label, multicentre, randomised, controlled trial, was done in 14 clinical centres across England and Scotland. We included children aged 2-15 years with stage 1-4 chronic kidney disease-ie, an estimated glomerular filtration rate (eGFR) higher than 15 mL/min per 1·73 m2-and who could be followed up for 2 years. Children on antihypertensive medication were eligible as long as it could be changed to angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) if they were not already receiving these therapies. Participants were randomly assigned (1:1) to standard treatment (auscultatory office systolic blood pressure target between the 50th and 75th percentiles) or intensive treatment (systolic target <40th percentile) by the chief investigator using a rapid, secure, web-based randomisation system. ACE inhibitors or ARBs were used as first-line agents, with the dose titrated every 2-4 weeks to achieve the target blood pressure levels. The primary outcome was mean annual difference in left ventricular mass index (LVMI) by echocardiography measured by a masked observer and was assessed in the intention-to-treat population, defined as all the children who underwent randomisation irrespective of the blood pressure reached. Secondary and safety outcomes were the differences between groups in mean left ventricular relative wall thickness, renal function, and adverse effects and were also assessed in the intention-to-treat population. This trial is registered with ISRCTN, ISRCTN25006406.Between Oct 30, 2012, and Jan 5, 2017, 64 participants were randomly assigned to the intensive treatment group and 60 to the standard treatment group (median age of participants was 10·0 years [IQR 6·8-12·6], 69 [56%] were male and 107 [86%] were of white ethnicity). Median follow-up was 38·7 months (IQR 28·1-52·2). Blood pressure was lower in the intensive treatment group compared with standard treatment group (mean systolic pressure lower by 4 mm Hg, p=0·0012) but in both groups was close to the 50th percentile. The mean annual reduction in LVMI was similar for intensive and standard treatments (-1·9 g/m2·7 [95% CI -2·4 to -1·3] vs -1·2 g/m2·7 [-1·5 to 0·8], with a treatment effect of -0·7 g/m2·7 [95% CI -1·9 to 2·6] per year; p=0·76) and mean value in both groups at the end of follow-up within the normal range. At baseline, elevated relative wall thickness was more marked than increased LVMI and a reduction in relative wall thickness was greater for the intensive treatment group than for the standard treatment group (-0·010 [95% CI 0·015 to -0·006] vs -0·004 [-0·008 to 0·001], treatment effect -0·020 [95% CI -0·039 to -0·009] per year, p=0·0019). Six (5%) participants reached end-stage kidney disease (ie, an eGFR of <15 mL/min per 1·73 m2; three in each group) during the course of the study. The risk difference between treatment groups was 0·02 (95% CI -0·15 to 0·19, p=0·82) for overall adverse events and 0·07 (-0·05 to 0·19, p=0·25) for serious adverse events. Intensive treatment was not associated with worse renal outcomes or greater adverse effects than standard treatment.These results suggest that cardiac remodelling in children with chronic kidney disease is related to blood pressure control and that a target office systolic blood pressure at the 50th percentile is close to the optimal target for preventing increased left ventricular mass.British Heart Foundation." @default.
• W4310081041 created "2022-11-30" @default.
• W4310081041 creator A5009703434 @default.
• W4310081041 creator A5014616545 @default.
• W4310081041 creator A5018257188 @default.
• W4310081041 creator A5019813963 @default.
• W4310081041 creator A5046107697 @default.
• W4310081041 creator A5047982811 @default.
• W4310081041 creator A5055366797 @default.
• W4310081041 creator A5056362398 @default.
• W4310081041 creator A5062400044 @default.
• W4310081041 creator A5072277459 @default.
• W4310081041 creator A5075056333 @default.
• W4310081041 creator A5075862352 @default.
• W4310081041 creator A5079865028 @default.
• W4310081041 creator A5083143327 @default.
• W4310081041 creator A5084096891 @default.
• W4310081041 creator A5084713803 @default.
• W4310081041 creator A5085168314 @default.
• W4310081041 creator A5065001617 @default.
• W4310081041 date "2023-01-01" @default.
• W4310081041 modified "2023-10-11" @default.
• W4310081041 title "Intensive compared with less intensive blood pressure control to prevent adverse cardiac remodelling in children with chronic kidney disease (HOT-KID): a parallel-group, open-label, multicentre, randomised, controlled trial" @default.
• W4310081041 cites W1968177453 @default.
• W4310081041 cites W1992141724 @default.
• W4310081041 cites W2001591759 @default.
• W4310081041 cites W2044861416 @default.
• W4310081041 cites W2068797950 @default.
• W4310081041 cites W2111039395 @default.
• W4310081041 cites W2113319100 @default.
• W4310081041 cites W2119487310 @default.
• W4310081041 cites W2122855609 @default.
• W4310081041 cites W2124624517 @default.
• W4310081041 cites W2124809323 @default.
• W4310081041 cites W2125487346 @default.
• W4310081041 cites W2126411348 @default.
• W4310081041 cites W2127917322 @default.
• W4310081041 cites W2160263067 @default.
• W4310081041 cites W2189612961 @default.
• W4310081041 cites W2297128749 @default.
• W4310081041 cites W2491849061 @default.
• W4310081041 cites W2747721206 @default.
• W4310081041 cites W3132757566 @default.
• W4310081041 cites W4251458288 @default.
• W4310081041 doi "https://doi.org/10.1016/s2352-4642(22)00302-9" @default.
• W4310081041 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36442482" @default.
• W4310081041 hasPublicationYear "2023" @default.
• W4310081041 type Work @default.
• W4310081041 citedByCount "5" @default.
• W4310081041 countsByYear W43100810412023 @default.
• W4310081041 crossrefType "journal-article" @default.
• W4310081041 hasAuthorship W4310081041A5009703434 @default.
• W4310081041 hasAuthorship W4310081041A5014616545 @default.
• W4310081041 hasAuthorship W4310081041A5018257188 @default.
• W4310081041 hasAuthorship W4310081041A5019813963 @default.
• W4310081041 hasAuthorship W4310081041A5046107697 @default.
• W4310081041 hasAuthorship W4310081041A5047982811 @default.
• W4310081041 hasAuthorship W4310081041A5055366797 @default.
• W4310081041 hasAuthorship W4310081041A5056362398 @default.
• W4310081041 hasAuthorship W4310081041A5062400044 @default.
• W4310081041 hasAuthorship W4310081041A5065001617 @default.
• W4310081041 hasAuthorship W4310081041A5072277459 @default.
• W4310081041 hasAuthorship W4310081041A5075056333 @default.
• W4310081041 hasAuthorship W4310081041A5075862352 @default.
• W4310081041 hasAuthorship W4310081041A5079865028 @default.
• W4310081041 hasAuthorship W4310081041A5083143327 @default.
• W4310081041 hasAuthorship W4310081041A5084096891 @default.
• W4310081041 hasAuthorship W4310081041A5084713803 @default.
• W4310081041 hasAuthorship W4310081041A5085168314 @default.
• W4310081041 hasBestOaLocation W43100810411 @default.
• W4310081041 hasConcept C126322002 @default.
• W4310081041 hasConcept C141071460 @default.
• W4310081041 hasConcept C159641895 @default.
• W4310081041 hasConcept C164705383 @default.
• W4310081041 hasConcept C197934379 @default.
• W4310081041 hasConcept C2778653478 @default.
• W4310081041 hasConcept C2908647359 @default.
• W4310081041 hasConcept C71924100 @default.
• W4310081041 hasConcept C84393581 @default.
• W4310081041 hasConcept C99454951 @default.
• W4310081041 hasConceptScore W4310081041C126322002 @default.
• W4310081041 hasConceptScore W4310081041C141071460 @default.
• W4310081041 hasConceptScore W4310081041C159641895 @default.
• W4310081041 hasConceptScore W4310081041C164705383 @default.
• W4310081041 hasConceptScore W4310081041C197934379 @default.
• W4310081041 hasConceptScore W4310081041C2778653478 @default.
• W4310081041 hasConceptScore W4310081041C2908647359 @default.
• W4310081041 hasConceptScore W4310081041C71924100 @default.
• W4310081041 hasConceptScore W4310081041C84393581 @default.
• W4310081041 hasConceptScore W4310081041C99454951 @default.
• W4310081041 hasIssue "1" @default.
• W4310081041 hasLocation W43100810411 @default.
• W4310081041 hasLocation W43100810412 @default.
• W4310081041 hasLocation W43100810413 @default.
• W4310081041 hasOpenAccess W4310081041 @default.
• W4310081041 hasPrimaryLocation W43100810411 @default.
• W4310081041 hasRelatedWork W113810927 @default.
• W4310081041 hasRelatedWork W1586374228 @default.

• next